Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,